{"id":"W3167855488","doi":"10.1016/j.annonc.2021.05.353","title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":278,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Institutes for BioMedical Research; Astex Pharmaceuticals","keywords":"Medicine; Fulvestrant; Internal medicine; Hazard ratio; Population; Breast cancer; Placebo; Metastatic breast cancer; Progression-free survival; Clinical endpoint; Oncology; Cancer; Randomized controlled trial; Gastroenterology; Confidence interval; Chemotherapy; Estrogen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001063412,0.0004857282,0.002456988,0.0001656542,0.0001513445,0.00001879772,0.0002606466,0.0002351528,0.0007674973],"category_scores_gemma":[0.0002773476,0.0003348687,0.000230853,0.000447331,0.0006769531,0.0003261646,0.0000541309,0.0004811682,0.00000290571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004709397,"about_ca_system_score_gemma":0.001182042,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003499217,"about_ca_topic_score_gemma":0.0001972258,"domain_scores_codex":[0.9958178,0.001087515,0.001100195,0.0006680652,0.000474279,0.0008521482],"domain_scores_gemma":[0.9957386,0.001704709,0.0007825748,0.0003748723,0.001170896,0.000228369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8846304,0.001843697,0.00003104082,0.00005985728,0.001359015,0.00009446558,0.004889777,0.00004962413,0.08075035,0.0007110148,0.0003530891,0.02522764],"study_design_scores_gemma":[0.951797,0.01434466,0.004518868,0.0001513401,0.0002141405,0.0001149614,0.002573275,0.00002920755,0.02138126,0.00115568,0.003257031,0.000462569],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9741296,0.001107716,0.000340599,0.01746216,0.0002847727,0.004189741,0.001942044,0.00005400893,0.0004893162],"genre_scores_gemma":[0.9915453,0.001140194,0.001462855,0.002622937,0.0003925349,0.001974408,0.0004822472,0.00008174973,0.000297735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06716657,"threshold_uncertainty_score":0.9999104,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04265747474552653,"score_gpt":0.3792816454752698,"score_spread":0.3366241707297433,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}